321 related articles for article (PubMed ID: 34202541)
1. Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases.
Hyun S; Shin D
Life (Basel); 2021 Jun; 11(7):. PubMed ID: 34202541
[TBL] [Abstract][Full Text] [Related]
2. PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.
Inuzuka H; Liu J; Wei W; Rezaeian AH
Acta Mater Med; 2022; 1(1):24-41. PubMed ID: 35237768
[TBL] [Abstract][Full Text] [Related]
3. Advancement of targeted protein degradation strategies as therapeutics for undruggable disease targets.
Kannan MP; Sreeraman S; Somala CS; Kushwah RB; Mani SK; Sundaram V; Thirunavukarasou A
Future Med Chem; 2023 May; 15(10):867-883. PubMed ID: 37254917
[TBL] [Abstract][Full Text] [Related]
4. Protein Quality Control by Molecular Chaperones in Neurodegeneration.
Ciechanover A; Kwon YT
Front Neurosci; 2017; 11():185. PubMed ID: 28428740
[TBL] [Abstract][Full Text] [Related]
5. Advancing targeted protein degradation for metabolic diseases therapy.
Zhou QQ; Xiao HT; Yang F; Wang YD; Li P; Zheng ZG
Pharmacol Res; 2023 Feb; 188():106627. PubMed ID: 36566001
[TBL] [Abstract][Full Text] [Related]
6. Novel Molecular Targets and Mechanisms for Neuroprotective Modulation in Neurodegenerative Disorders.
Azari A; Goodarzi A; Jafarkhani B; Eghbali M; Karimi Z; Hosseini Balef SS; Irannejad H
Cent Nerv Syst Agents Med Chem; 2022; 22(2):88-107. PubMed ID: 35713146
[TBL] [Abstract][Full Text] [Related]
7. Degradation of misfolded proteins in neurodegenerative diseases: therapeutic targets and strategies.
Ciechanover A; Kwon YT
Exp Mol Med; 2015 Mar; 47(3):e147. PubMed ID: 25766616
[TBL] [Abstract][Full Text] [Related]
8. Design, Synthesis and Biological Evaluation of α-Synuclein Proteolysis-Targeting Chimeras.
Wen T; Chen J; Zhang W; Pang J
Molecules; 2023 May; 28(11):. PubMed ID: 37298935
[TBL] [Abstract][Full Text] [Related]
9. Autophagy and apoptosis dysfunction in neurodegenerative disorders.
Ghavami S; Shojaei S; Yeganeh B; Ande SR; Jangamreddy JR; Mehrpour M; Christoffersson J; Chaabane W; Moghadam AR; Kashani HH; Hashemi M; Owji AA; Łos MJ
Prog Neurobiol; 2014 Jan; 112():24-49. PubMed ID: 24211851
[TBL] [Abstract][Full Text] [Related]
10. Targeted protein degraders march towards the clinic for neurodegenerative diseases.
Kumar D; Hassan MI
Ageing Res Rev; 2022 Jun; 78():101616. PubMed ID: 35378298
[TBL] [Abstract][Full Text] [Related]
11. Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates.
Park H; Kang JH; Lee S
Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32397599
[TBL] [Abstract][Full Text] [Related]
12. The interrelationship of proteasome impairment and oligomeric intermediates in neurodegeneration.
Deger JM; Gerson JE; Kayed R
Aging Cell; 2015 Oct; 14(5):715-24. PubMed ID: 26053162
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Effective Dual PROTAC Degraders for Neurodegenerative Disease-Associated Aggregates.
Zhu W; Zhang W; Chen J; Tong Y; Xu F; Pang J
J Med Chem; 2024 Mar; 67(5):3448-3466. PubMed ID: 38356330
[TBL] [Abstract][Full Text] [Related]
14. Collective roles of molecular chaperones in protein degradation pathways associated with neurodegenerative diseases.
Luo GR; Le WD
Curr Pharm Biotechnol; 2010 Feb; 11(2):180-7. PubMed ID: 20166963
[TBL] [Abstract][Full Text] [Related]
15. Research progress of PROTACs for neurodegenerative diseases therapy.
Cai Z; Yang Z; Li H; Fang Y
Bioorg Chem; 2024 Jun; 147():107386. PubMed ID: 38643565
[TBL] [Abstract][Full Text] [Related]
16. Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier.
Tashima T
Antibodies (Basel); 2023 Jun; 12(3):. PubMed ID: 37489365
[TBL] [Abstract][Full Text] [Related]
17. Walking the tightrope: proteostasis and neurodegenerative disease.
Yerbury JJ; Ooi L; Dillin A; Saunders DN; Hatters DM; Beart PM; Cashman NR; Wilson MR; Ecroyd H
J Neurochem; 2016 May; 137(4):489-505. PubMed ID: 26872075
[TBL] [Abstract][Full Text] [Related]
18. Multifaceted targeted protein degradation systems for different cellular compartments.
Zorca CE; Fallahi A; Luo S; Eldeeb MA
Bioessays; 2022 Jun; 44(6):e2200008. PubMed ID: 35417040
[TBL] [Abstract][Full Text] [Related]
19. Proteolysis targeting chimera technology: a novel strategy for treating diseases of the central nervous system.
Ma K; Han XX; Yang XM; Zhou SL
Neural Regen Res; 2021 Oct; 16(10):1944-1949. PubMed ID: 33642364
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
